Sarcopenia: difference between revisions
Diff·revision 4 → 5·07:48, 28 Dec 2024
Difference between revision 4 and revision 5 of Sarcopenia. 3 lines changed; the page grew by 460 bytes.
| Revision 4 — 15:28, 17 Dec 2024 A1c_Alder (talk) convert a hard-coded date to the house format 1,830 bytes +233 | Revision 5 — 07:48, 28 Dec 2024 Chromatokid (talk) rm the claim that the marker predicts outcome; the cited study is cross-sectional 2,290 bytes +460 | ||
|---|---|---|---|
| 10 | The reordering matters for how the topic is discussed in the context of weight reduction. A fall in lean mass measured by [[Body composition assessment|body composition assessment]] is not sarcopenia; a fall in strength or function is the finding that would be.{{r|cruzjentoft2019}} | 10 | The reordering matters for how the topic is discussed in the context of weight reduction. A fall in lean mass measured by [[Body composition assessment|body composition assessment]] is not sarcopenia; a fall in strength or function is the finding that would be.{{r|cruzjentoft2019}} |
| 11 | 11 | ||
| + | 12 | Concern about sarcopenia during substantial pharmacological weight loss is reasonable in principle, particularly in older people and those with low muscle mass at baseline, and the evidence addressing it directly is limited.{{r|wilding2021}} | |
| + | 13 | ||
| 12 | == Definition and assessment == | 14 | == Definition and assessment == |
| 13 | Consensus definitions require low muscle strength for a probable diagnosis, confirmed by low muscle quantity or quality, with poor physical performance indicating severity.{{r|cruzjentoft2019}} | 15 | Consensus definitions require low muscle strength for a probable diagnosis, confirmed by low muscle quantity or quality, with poor physical performance indicating severity.{{r|cruzjentoft2019}} |
| ⋮ | ⋮ | ||
| 24 | {{reflist}} | 26 | {{reflist}} |
| 25 | <ref name="cruzjentoft2019">Cruz-Jentoft AJ, Bahat G, Bauer J, et al. "Sarcopenia: revised European consensus on definition and diagnosis." ''Age and Ageing'' 48(1):16–31 (2019). DOI:10.1093/ageing/afy169. PMID 30312372.</ref> | 27 | <ref name="cruzjentoft2019">Cruz-Jentoft AJ, Bahat G, Bauer J, et al. "Sarcopenia: revised European consensus on definition and diagnosis." ''Age and Ageing'' 48(1):16–31 (2019). DOI:10.1093/ageing/afy169. PMID 30312372.</ref> |
| + | 28 | <ref name="wilding2021">Wilding JPH, Batterham RL, Calanna S, et al. "Once-weekly semaglutide in adults with overweight or obesity." ''New England Journal of Medicine'' 384(11):989–1002 (2021). PMID 33567185.</ref> | |
| 26 | 29 | ||
| 27 | {{DEFAULTSORT:Sarcopenia}} | 30 | {{DEFAULTSORT:Sarcopenia}} |